Clinical trial · Interventional
Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor
A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor
NCT01212341CI-TRIAL-00011801MG4101completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis. These cells were processed based on a novel method for ex vivo activation and expansion using an irradiated and activated autologous feeder cell system. MG4101 has anti-tumor activities against various tumors including malignant lymphomas in vitro as well as in vivo tumor model.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Lymphomas | Lymphoma | ALIAS | 0.90 |
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Allogeneic NK cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Singe-dose infusion
- description
- Cohort 1: 1x10\^6 cells/kg Cohort 2: 1x10\^7 cells/kg
- interventionNames
- Biological: Allogeneic NK cells
- type
- EXPERIMENTAL
- label
- Repeated dose infusion
- description
- Cohort 3: 1x10\^6 cells/kg Cohort 4: 3x10\^6 cells/kg Cohort 5: 1x10\^7 cells/kg Cohort 6: 3x10\^7 cells/kg
- interventionNames
- Biological: Allogeneic NK cells
Primary outcomes (1)
- measure
- To determine the MTD of allogenetic NK cells
- timeFrame
- 4-5 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older * Histologically or cytologically confirmed malignant lymphoma or solid tumor * After the failure of standard treatment * KPS \>70 or ECOG PS 0-2 * Adequate bone marrow, renal, and liver functions * Expected survival at least 3 months * Informed consent Exclusion Criteria: * Pregnancy or lactating woman * HIV patients * Prior exposure to cell-based therapy * Hypersensitivity to interleukin-2 * Patients with autoimmune disease
References
Publications (0)
Data not yet available
No reference posted for this study.